RNLXY.US Renalytix Plc

Healthcare Health Information Services USA Stocks
3.67 USD
Close of Nov 18, 2026
0.9990 4.94
Market cap
USD 49.2M
P/E
-
P/B
18.77x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is RNLXY.US undervalued?

Graham number

The Graham number of Renalytix Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Renalytix Plc fundamental analysis

No fundamental analysis for Renalytix Plc yet.

Renalytix Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Renalytix Plc

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The co…

Full company profile